secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061473
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora reports Q4 2023 net loss of $108.7M; cash $463.8M into 2026
-------------------------------------------------------------------

- Net loss Q4 2023: $108.7M vs $28.1M in Q4 2022; full year net loss $235.9M vs $130.9M.
- Cash, cash equivalents and marketable securities $463.8M as of Dec 31, 2023; expected to fund operations into 2026.
- R&D expenses Q4 2023: $38.9M, up from $23.5M, driven by navacaprant Phase 3 startup and IPR&D costs.
- Topline Phase 3 KOASTAL-1 data for navacaprant in MDD expected H2 2024; KOASTAL-2/3 data in H1 2025.
- Phase 1 data for NMRA-266 (M4 PAM) in healthy adults expected mid-2024; Phase 1b in schizophrenia planned H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/0001193125-24-061473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312524061473/d803910d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer